# EDGAR Filing Document

**Accession Number:** 0001042418
**File Stem:** 0001493152-25-019381
**Filing Date:** 2025-10
**Character Count:** 113960
**Document Hash:** 69651aa82dea8193a8369f93b32514cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-019381.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0001493152-25-019381

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251024

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251024

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibitor Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001042418
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 541641133
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13467
- **FILM NUMBER:** 251417286

**BUSINESS ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609
- **BUSINESS PHONE:** (813) 766-2462

**MAIL ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HedgePath Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130816

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COMMONWEALTH BIOTECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19970714

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or Section 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 24, 2025 (October 21, 2025)**

**Inhibitor Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-13467** | **30-0793665** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission<br> File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**3014 West Palmira Ave., Suite 302**

**Tampa, FL 33629 (813) 864-2562**

**(Address, including Zip Code and Telephone Number, including Area Code, of Principal Executive Offices)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item** **1.01.** | **Entry into a Material Definitive Agreement.** |

---

On October 21, 2025, Inhibitor Therapeutics, Inc. (the "<u>Company</u>") entered into a performance-based master services agreement (the "<u>Agreement</u>") with Frameshift Management, Inc., a Delaware corporation (the "<u>Consultant</u>"), pursuant to which the Consultant shall provide the Company with consulting services for biostatistics, regulatory, business development and strategic consulting in support of Company's programs in basal cell carcinomas in Gorlin's syndrome, and related services that the Company may request (the "<u>Services</u>"). The Consultant's program of support will utilize the Company's proprietary new formulation of itraconazole, with the unvested equity compensation realized only after certain requirements described in the Agreement. Pursuant to the Agreement the Consultant will provide the Services to the Company, which commenced on October 21, 2025, and continues for an indefinite period until terminated in accordance with the terms of the Agreement, as specified in one or more statements of work (the "<u>SOW</u>"). The term and scope of each project will be set forth in the applicable SOW. As consideration for such services, the Consultant will be compensated at a previously agreed upon rate.

In addition to performance commitments and payment terms, the Agreement includes customary provisions relating to confidentiality, indemnification and liability, intellectual property, data protection, termination rights, compliance with applicable laws and dispute resolution.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as <u>Exhibit 10.1</u> to this Current Report on Form 8-K and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

Effective on October 21, 2025, the Board of Directors (the "<u>Board</u>") of the Company approved the Inhibitor Therapeutics, Inc. 2025 Equity Incentive Plan (the "<u>2025 Plan</u>"). The material terms of the 2025 Plan are summarized as follows:

*Eligibility*

The Administrator may grant awards to any service providers.

*Administration*

The 2025 Plan will be administered by the Board or one more committees or subcommittees of the Board, which will be comprised of not less than one member (collectively, the "Administrator"). The Administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the administration of the 2025 Plan, subject to the 2025 Plan's express terms and conditions. The Administrator will also set the terms and conditions of all awards under the 2025 Plan, including any vesting and vesting acceleration conditions.

*Share Reserve*

The maximum aggregate number of shares of the Company's common stock that may be issued under the 2025 Plan is 20 million shares of common stock.

*Types of Awards*

The 2025 Plan provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock- or cash-based awards (collectively, "awards").

The foregoing description of the 2025 Plan is not complete and is subject to, and qualified in its entirety by, to the full text of the 2025 Plan, a copy of which is attached as <u>Exhibit 10.2</u> to this Current Report and is incorporated herein by reference.

*Shareholder Approval*

 

The Company plans to solicit/receive shareholder approval within 12 months of the effective date of adoption of the Plan by the Board. Plan provides that if such approval is not timely received the Plan terminates, as do any awards made thereunder.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) The following exhibit is filed with this report.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 10.1+ | [Master Services Agreement, dated October 21, 2025](ex10-1.htm) |
| 10.2 | [Inhibitor Therapeutics, Inc. 2025 Equity Incentive Plan](ex10-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

+ Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: October 24, 2025 | INHIBITOR THERAPEUTICS, INC. | INHIBITOR THERAPEUTICS, INC. |
|  | By: | */s/ Francis E. O'Donnell* |
|  | Name: | Francis E. O'Donnell |
|  | Title: | Executive Chairman and CEO |

---

## Exhibit 10.1

**Exhibit 10.1**

<u>Certain personally identifiable information has been omitted from this exhibit pursuant to Item 601(a)(6) of Regulation S-K. [\*\*\*] indicates that information has been redacted.</u>

<u>MASTER SERVICES AGREEMENT</u>

THIS MASTER SERVICES AGREEMENT (the "Agreement") is made and entered into as of this 21st day of October, 2025, by and between Frameshift Management, Inc. (hereinafter referred to as "Consultant"), a Delaware corporation with an address at 1108 Lavaca St, Suite 110-329, Austin, TX 78701, and Inhibitor Therapeutics, Inc. (the "Company") a Delaware corporation with offices at 3014 West Palmira Ave., Suite 302, Tampa, FL 33629, (hereinafter Consultant and Company may be referred to individually as "Party" or jointly as "the Parties").

RECITALS

WHEREAS, the Company desires to engage Consultant to provide consulting services for biostatistics, regulatory, business development and strategic consulting in support of Company's programs in basal cell carcinomas in Gorlin's syndrome, and related services that the Company may request ("the Services"); and

WHEREAS, the Consultant has the skill, expertise, and know-how in certain areas needed to perform the above referenced Services;

NOW, THEREFORE, in exchange for good and valuable consideration and promises, the sufficiency of which is hereby acknowledged, the Parties agree as follows:

1. <u>Engagement</u>.
 The Company hereby engages the Consultant and the Consultant hereby accepts such engagement,
 upon the terms and conditions set forth in this Agreement, for one or more projects. The
 specific details of each project, including the services to be performed, compensation, and
 term, shall be set forth in separate statements of work ("Statements of Work"
 or "SOWs") executed under this agreement.

2. <u>Term</u>.
 This Agreement shall commence on October 21, 2025, and shall continue for an indefinite period
 until terminated in accordance with this Agreement. The term of any specific project shall
 be set forth in the applicable SOW. During the term of each SOW, Consultant agrees that its
 staff will be reasonably available to the Company by remote internet access, at its place
 of business, by teleconference, or at such location as the Company may reasonably request,
 from time to time, to enable Consultant to perform the Services requested. Consultant shall
 be compensated for this engagement in accordance with the compensation rate set forth in
 the applicable SOW.

3. <u>Duties</u>.
 Upon completion of a signed SOW by the Parties, the Consultant shall provide general consulting
 services and assistance to the Company related to the performance of the Services described
 in such SOW.

4. <u>Billing and Performance-based Compensation.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. As
 consideration for all services rendered by Consultant under this Agreement, the Company shall
 pay Consultant at the rate of specified in the applicable SOW

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Consultant
 shall be reimbursed for business travel and other expenses incurred in performance of the
 services, as set forth in the applicable SOW or as otherwise approved by the Company. Travel
 expenses shall be pre-approved and governed by Consultant's 2025 Travel and Expense
 Policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Consultant
 shall issue monthly written invoices to the Company for consulting fees and expenses under
 this Agreement. Any payment due Consultant shall be made within fifteen (15) days of receipt
 of an invoice, via wire or ACH transfer.

5. <u>Security and Computer Policies</u>. Consultant shall be subject to and shall at all times conform
 to the Company security rules and requirements for the protection of the Company's
 facilities, materials, information, equipment and personnel. Additionally, Consultant shall
 comply with all rules of the Company concerning access to computers and networks of the Company,
 and its affiliates, and use of computer data and software.

6. <u>Independent Contractor.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The
 relationship of the Consultant to the Company shall be that of an independent contractor,
 and neither this Agreement nor any conduct hereunder shall be deemed to create a relationship
 of employer-employee, partnership, joint venture, subcontractor, or any other teaming or
 common enterprise. Consultant shall be responsible for payment of all taxes including Federal,
 State and Local taxes arising out of Consultant's activities in accordance with this
 Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The
 Consultant shall have no authority to bind the Company to, or assume, enter into, or act
 on behalf of the Company for any obligation, agreement, or act.

7. <u>Confidentiality and Non-Circumvention.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. During
 the term of this Agreement, and at all times thereafter, the Consultant shall keep confidential
 and not disclose, any confidential and proprietary information learned as a result of this
 Agreement or any SOW, whether belonging to Company or its clients, to any other party other
 than in connection with Consultant's assigned duties and activities hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Consultant
 shall not, without the prior written consent of the Company, (a) utilize any confidential
 information to circumvent or compete with the Company, or (b) utilize information lawfully
 furnished or disclosed to Consultant by a non-party to this Agreement, or information independently
 developed by Consultant relative to the Services under this Agreement, to circumvent or compete
 with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. It
 is expressly agreed that the identities of clients, governmental authorities, corporations,
 and any other relevant third parties and contracts, processes, etc. constitute confidential
 information under this Agreement, and Consultant hereby expressly agrees that it, including,
 but not limited to its associates, agents, affiliates, representatives, contractors, shall
 not enter into a transaction, directly or indirectly, or attempt or do business with the
 Company's client or with any third party identified or introduced by the Company without
 the prior written consent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Consultant
 and Company will enter into a separate form of Confidentiality Agreement (the "CDA").
 The provisions of confidentiality and non-disclosure contained in that NDA shall be incorporated
 herein as if set forth at length herein.

8. <u>Non-Compete</u>.
 Regarding any of the information referred to in this Agreement, the Consultant agrees not
 to use the same to compete with the Company during the term of this Agreement.

9. <u>Inventions and Pre-Existing Intellectual Property</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Any
 and all inventions, discoveries, developments, improvements, innovations and copyrightable
 material and other intellectual property rights created or conceived by Consultant during
 this engagement that are directly related to Company's programs in basal cell carcinomas
 in Gorlin's syndrome, or incorporate any of Company's confidential or proprietary
 materials or intellectual property, shall be the exclusive property of Company and considered
 works made for hire by Consultant for the Company. For the avoidance of doubt, Consultant
 hereby grants, transfers and assigns all right, title and interest in the same to Company,
 including without limitation the copyright therein throughout the world. Consultant will,
 at the request and cost of the Company, promptly sign, make and do all such deeds, documents,
 acts and things as the Company may reasonably require in order to effectuate the purpose
 of this paragraph.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Notwithstanding
 Section 9(a), any and all methods, software tools, AI models, prompts, know-how and other
 intellectual property developed by Consultant prior to or independently of this engagement
 (including any modifications or improvements thereto, even if developed during the term of
 this Agreement) (collectively, the "Consultant IP") – shall remain the
 sole and exclusive property of Consultant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. In
 any event where Consultant's deliverables under this Agreement incorporate or derive
 from Consultant IP, Consultant hereby grants Company a non-exclusive, non-transferable, worldwide
 license to use such Consultant IP solely as embedded in, and to the extent required to exploit,
 the deliverable, conditioned upon full payment of all amounts due.

10. <u>Termination</u>.
 Either Party may, at any time, terminate this Agreement or any SOW (a) for material breach,
 if the breaching Party fails to cure within 15 days after written notice, or (b) without
 cause upon 45 days prior written notice. In the event of a termination under this paragraph,
 Consultant shall complete as soon as possible any tasks pending at the time of termination
 unless directed otherwise by the Company, and shall promptly return to the Company all property,
 documents, and other information belonging to the Company. If Consultant's engagement
 hereunder is terminated for any reason, Company shall pay Consultant any unpaid fees and
 reimburse approved expenses through the Termination Date of the Agreement or the applicable
 SOW. This Agreement shall otherwise terminate at the conclusion of the Term outlined herein,
 unless the parties agree in writing to an extension or modification of same.

11. <u>Force Majeure</u>. Neither Party shall be liable for any delay or failure to perform caused by
 acts beyond its reasonable control, including acts of God, natural disasters, epidemics,
 cyber-attacks, labor disputes, war, terrorism, or governmental action, provided that the
 affected Party (a) promptly notifies the other, (b) uses commercially reasonable efforts
 to mitigate, and (c) resumes full performance as soon as practicable. If a force-majeure
 event persists for more than 30 days, either Party may terminate the affected SOW upon 10
 days' notice.

12. <u>Acknowledgement</u>.
 Company and Consultant hereby acknowledge and agree that the terms and conditions contained
 in this Agreement are fair and reasonable and necessary for the protection of the legitimate
 business interests of Company and Consultant.

13. <u>Prohibition on Assignment</u>. Because the skill, expertise, and know-how of Consultant is of material
 inducement to the Company entering into this Agreement, this Agreement shall not be assignable,
 either in whole or in part, by Consultant, nor may Consultant delegate any or all duties,
 responsibilities or obligations hereunder.

14. <u>Equitable Relief</u>. Any breach of the term and conditions of this Agreement or any SOW by Consultant
 will result in material damage to the Company. It would be difficult to establish the monetary
 value of such damage. Therefore, Company shall be entitled to injunctive relief by a court
 of appropriate jurisdiction in the event of Consultant's breach or threatened breach
 of any of the terms of this Agreement or any SOW.

15. <u>Indemnification</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Consultant
 shall defend, indemnify, and hold harmless Company from third-party claims arising out of
 Consultant's gross negligence or willful misconduct in performing the Services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Company
 shall defend, indemnify, and hold harmless Consultant from third-party claims alleging that
 materials or instructions supplied by Company infringe any intellectual-property right, or
 arising from Company's negligence or willful misconduct.

16. <u>Limitation of Liability</u>. EXCEPT FOR (a) A PARTY'S WILLFUL MISCONDUCT OR GROSS NEGLIGENCE and
 (b) EACH PARTY'S INDEMNITY OBLIGATIONS UNDER SECTION 15, NEITHER PARTY SHALL BE LIABLE
 FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, PUNITIVE, OR EXEMPLARY DAMAGES, EVEN
 IF ADVISED OF THE POSSIBILITY. EACH PARTY'S AGGREGATE LIABILITY UNDER THIS AGREEMENT
 SHALL NOT EXCEED THE FEES PAID OR PAYABLE UNDER THE RELEVANT SOW.

17. <u>Governing Law and Forum</u>. This Agreement, including its validity, construction, interpretation and
 enforcement is governed by the laws of the State of Florida, without regard to the principle
 of conflicts of law. Company and Consultant agree that they will not institute any action
 against the other except in the state or federal courts of general jurisdiction in Hillsborough
 County, State of Florida, and they irrevocably submit to the jurisdiction of such courts
 and waive any objection they may have to either the jurisdiction or venue of such court.
 15. Notices. All notices, requests, demands and other communication required or permitted
 hereunder, shall be in writing and shall be deemed to have been given if delivered in person
 or by courier, or mailed by certified mail, postage prepaid, as follows:

If to Company:

Inhibitor Therapeutics, Inc.

3014 West Palmira Ave Suite 302

Tampa, FL 33629 Attn: James McNulty, CFO

Email: <u>jamcnulty@usrxpharma.com</u>

If to Consultant:

Frameshift Management, Inc.

1108 Lavaca St, Suite 110-329

Austin, TX 78701

Email: <u>legal@frameshiftmgmt.com</u>

Or to such other address as any Party may notify the other in the manner provided above.

18. <u>Modification and Waiver</u>. Failure of either Party to insist, in one or more instances, on performance
 by the other in strict accordance with the terms and conditions of this Agreement shall not
 be deemed a waiver or relinquishment of any right granted in this Agreement or of the future
 performance of any such term or condition or of any other term or condition of this Agreement,
 unless such waiver is contained in a writing signed by the Party making the waiver. This
 Agreement may be modified or amended only in writing signed by all of the Parties hereto.

19. <u>Entire Agreement</u>. This Agreement, including any SOWs, exhibits or attachments hereto, constitutes
 the entire agreement between the Parties with respect to the subject matter hereof and supersedes
 all prior and contemporaneous agreements, understandings, representations, and communications,
 whether oral or written, relating to such subject matter—including any previous consulting
 agreement between the Parties. No amendment, modification, or waiver of any provision of
 this Agreement shall be effective unless in writing and signed by both Parties.

20. <u>Counterparts</u>.
 This Agreement may be executed in two or more counterparts, each of which shall be deemed
 an original but all of which together shall constitute one and the same instrument. The execution
 of this Agreement may be by actual, electronic or facsimile signature.

21. <u>Severability</u>.
 This Agreement is intended to be performed in accordance with, and only to the extent permitted
 by, all applicable laws, ordinances, rules and regulations. If any provision of this Agreement
 and the application of such provisions to other persons or circumstances shall not be affected
 thereby, but rather shall be enforced to the greatest extent permitted by law.

22. <u>Attorney's Fees</u>. In the event that there is any controversy or claim arising out of or relating
 to this Agreement, the prevailing party shall be entitled to recover its reasonable attorneys'
 fees, costs, and expenses from the non-prevailing party.

23. <u>Headings</u>.
 Section headings are intended for ease of reference only and are not to be considered part
 of this Agreement and are not intended to be a full and accurate description of the contents
 hereof.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first above

---

| | | | |
|:---|:---|:---|:---|
| **INHIBITOR THERAPEUTICS, INC.** | **INHIBITOR THERAPEUTICS, INC.** | **FRAMESHIFT MANAGEMENT, INC. (Consultant)** | **FRAMESHIFT MANAGEMENT, INC. (Consultant)** |
| By: |  | By: |  |
| Name: | Frank O'Donnell Jr | Name: | Jonathan P. Feldmann |
| Title: | CEO & Executive Chairman | Title: | Chief Operating Officer |
| Date: |  | Date: |  |

---

EXHIBIT A

<u>STATEMENT OF WORK No. 1</u>

This Statement of Work ("SOW") is entered into as of this 21st day of October, 2025, between Frameshift Management, Inc. ("Consultant") and Inhibitor Therapeutics, Inc. (the "Company"), pursuant to the Master Services Agreement (the "Agreement") between the Parties effective October 21, 2025.

1. <u>Project Title:</u> HP2001 Clinical Study Report Re-Analysis and Re-Framing

2. <u>Services and Deliverables</u>: This contract is a performance-based arrangement. Consultant shall perform the following services (the "Services"):

● **HP2001 Clinical Study Re-Analysis and Re-Framing** 

● Re-evaluation and analysis of patient-level data from HP2001, with a primary focus on the assignment of responses based upon the criteria set forth in the study's Statistical Analysis Plan.

● Comparison of that analysis with the evaluation criteria used in the approvals of vismodegib and sonidegib, and framing the results within the specific clinical context of BCCNS.

● The deliverables from this re-analysis will include documentation and presentation to management of the following:

● Regulatory Pathway Optimization: [\*\*\*]

● Endpoint Analysis: [\*\*\*]

● Reframing: [\*\*\*]

● Data Integrity Framework: [\*\*\*]

● Strategic Decision Support: [\*\*\*]

● **FDA Meeting Request and Preparation** 

● Based on the analysis above, we anticipate an opportunity to discuss the clinical path within a clinical advisory meeting (Type B, C or D) with FDA. This will include the following:

● Briefing booklet and formal meeting request

● Filing of an appropriate FDA meeting request, including briefing booklet and any necessary supporting materials.

● If FDA accepts a meeting request, we will provide meeting minutes and coordinate follow-up with the agency for final minutes.

● This is intended to be a preliminary, clinical advisory meeting with FDA. Additional follow-on work will be required for subsequent FDA submissions (including NDA filing).

3. <u>Future SOW</u>: A second stage of the project, outside of the scope of this SOW, anticipates supporting
 the Company through the NDA, including regulatory support, presenting and defending our work
 and the filings before FDA, assisting with the NDA's clinical and CMC reports assembly,
 and other necessary tasks. This will include delivering a comprehensive pre-NDA clinical
 strategy and a full HP2001 clinical study report with new analyses for the NDA filing. This
 is not included in the compensation or scope of this SOW. Consultant's preliminary
 estimate for the cost of that future SOW is <u>[\*\*\*].</u> Consultant will provide detailed
 proposal and revised costs based on the outcome of the FDA meeting described above and based
 on Company's successful completion of the formulation work for the CMC section of the
 NDA filing.

4. <u>Term</u>:
 The term of this SOW shall commence on October 21, 2025, and shall continue until the deliverables
 are completed, unless terminated earlier in accordance with the Agreement.

5. <u>Compensation</u>:
 For the Services performed under this Agreement, the Company shall pay Consultant the following
 fees:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Costs
 for the analysis and management presentation described above will be a fixed <u>[\*\*\*].</u> Costs for the FDA materials, meeting request, and regulatory work described above will be
 a minimum of <u>[\*\*\*],</u> with additional costs if the scope of regulatory work expands
 beyond <u>[\*\*\*]</u> hours (additional hours to be billed hourly). These costs will be split
 into two payments:

i <u>[\*\*\*]</u> upon contract execution

ii <u>[\*\*\*]</u> upon submission of the FDA meeting request and response from FDA (where the response may be acceptance of a meeting, declining a meeting, or providing written responses in lieu of a meeting).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Reasonable
 and pre-approved business travel and other expenses incurred in performance of the Services
 as per the terms of the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Invoices
 will be submitted, and payments will be made upon the terms of the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Upon
 submission of the briefing package 18,000,000 unvested 4-year warrants ("Warrants")
 to purchase an equivalent number of shares of Company common stock at the closing price on
 the day prior to execution of this Statement of Work, vesting upon one of the following:
 (1) license or sale of the Company's itraconazole program, (2) sale of a majority of
 the Company's equity (3) a merger or other change of control transaction wherein ownership/management
 of the Company's itraconazole program transfers to a third party, or (4) FDA's
 approval of the Company's itraconazole program followed by the company proceeding to
 commercialize rather than selling or licensing. Warrants will be issued to Frameshift Innovation
 LLC, include cashless/net share provisions, and will be governed by a separate Warrant agreement
 signed by Frameshift Innovation LLC and Company.

6. <u>Company Responsibilities</u>: Company will provide access to any documents and related data from
 prior studies necessary to complete the Services.

7. <u>Entire Agreement; Conflict</u>: This SOW, together with the Agreement, constitutes the entire agreement
 between the Parties with respect to the Services described herein and supersedes all prior
 discussions and understandings between the Parties relating to such Services. In the event
 of any conflict or inconsistency between the terms of this SOW and the Agreement, the terms
 of the Agreement shall prevail, unless this SOW explicitly states an intent to supersede
 a specific provision of the Agreement and is signed by both Parties.

Signature Page Follows

IN WITNESS WHEREOF, the parties have caused this SOW to be executed as of the date first above

---

| | | | |
|:---|:---|:---|:---|
| **INHIBITOR THERAPEUTICS, INC.** | **INHIBITOR THERAPEUTICS, INC.** | **FRAMESHIFT MANAGEMENT, INC. (Consultant)** | **FRAMESHIFT MANAGEMENT, INC. (Consultant)** |
| By: |  | By: |  |
| Name: | Frank O'Donnell Jr | Name: | Jonathan P. Feldmann |
| Title: | CEO & Executive Chairman | Title: | Chief Operating Officer |
| Date: |  | Date: |  |

---

## Exhibit 10.2

**Exhibit 10.2**

**Inhibitor Therapeutics, Inc.**

**2025 EQUITY INCENTIVE PLAN (Adopted as of October 21, 2025)**

1. <u>Purpose</u>.
 The purposes of this Plan are to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) attract,
 retain, and motivate Employees, Directors, and Consultants,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) provide
 additional incentives to Employees, Directors, and Consultants, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) promote
 the success of the Company's business,

by providing Employees, Directors, and Consultants with opportunities to acquire the Company's Shares, or to receive monetary payments based on the value of such Shares. Additionally, the Plan is intended to assist in further aligning the interests of the Company's Employees, Directors, and Consultants to those of its stockholders.

2. <u>Definitions</u>.
 As used herein, the following definitions will apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) " <u>Administrator</u> "
 means a committee of at least one Director of the Company as the Board may appoint to administer
 this Plan or, if no such committee has been appointed by the Board, the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) " <u>Applicable Laws</u> " means the requirements relating to the administration of equity-based awards
 or equity compensation plans under U.S. state corporate laws, U.S. federal and state securities
 laws, the Code, any stock exchange or quotation system on which the Shares are listed or
 quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or
 will be, granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) " <u>Award</u> "
 means, individually or collectively, a grant under the Plan of Stock Options, Stock Appreciation
 Rights, Restricted Stock, Restricted Stock Units, or Other Stock-Based Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) " <u>Award Agreement</u> " means the written or electronic agreement, consistent with the terms
 of the Plan, between the Company and the Participant, setting forth the terms, conditions,
 and restrictions applicable to each Award granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) " <u>Board</u> "
 means the Company's Board of Directors, as constituted from time to time and, where
 the context so requires, reference to the "Board" may refer to a committee to
 whom the Board has delegated authority to administer any aspect of this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) "Cause"
 shall have the meaning ascribed to such term, or term of similar effect, in any offer letter,
 employment, consulting, severance, or similar agreement, including any Award Agreement, between
 the Participant and the Company or any Subsidiary; provided, that in the absence of an offer
 letter, employment, severance, or similar agreement containing such definition, "Cause"
 means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any
 willful, material violation by the Participant of any law or regulation applicable to the
 business of the Company, a Subsidiary, or other affiliate of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the
 Participant's conviction for, or guilty plea to, a felony (or crime of similar magnitude
 under Applicable Laws outside the United States) or a crime involving moral turpitude, or
 any willful perpetration by the Participant of a common law fraud, act of material dishonesty,
 embezzlement, or misappropriation or similar conduct against the Company, a Subsidiary, or
 other affiliate of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the
 Participant's commission of an act of personal dishonesty which involves personal profit
 in connection with the Company, a Subsidiary, other affiliate of the Company, or any other
 entity having a business relationship with any of the foregoing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) any
 material breach or violation by the Participant of any fiduciary duties or duties of care
 to the Company or provision of any agreement or understanding between the Company, a Subsidiary,
 or other affiliate of the Company and the Participant regarding the terms of the Participant's
 service as an Employee, officer, Director, or Consultant to the Company, a Subsidiary, or
 other affiliate of the Company, including without limitation, the willful and continued failure
 or refusal of the Participant to perform the material duties required of such Participant
 as an Employee, officer, Director, or Consultant of the Company, a Subsidiary, or other affiliate
 of the Company, other than as a result of having a Disability, or a breach of any applicable
 invention assignment, confidentiality, non-competition, non-solicitation, restrictive covenant,
 or similar agreement between the Company, a Subsidiary, or other affiliate of the Company
 and the Participant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) any
 willful and continued refusal by the Participant to carry out a reasonable directive of the
 chief executive officer, the Board or the Participant's direct supervisor, which involves
 the business of the Company, a Subsidiary, or other affiliate of the Company and was capable
 of being lawfully performed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) the
 Participant's violation of the code of ethics of the Company or any Subsidiary;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) the
 Participant's disregard of the policies of the Company, a Subsidiary, or other affiliate
 of the Company so as to cause loss, harm, damage, or injury to the property, reputation,
 or employees of the Company, a Subsidiary, or other affiliate of the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) any
 other misconduct by the Participant that is injurious to the financial condition or business
 reputation of, or is otherwise injurious to, the Company, a Subsidiary, or other affiliate
 of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) " <u>Change in Control</u> " means the occurrence of any of the following events:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any
 "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act)
 becomes the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act),
 directly or indirectly, of securities of the Company representing more than fifty percent
 (50%) of the total voting power represented by the Company's then outstanding voting
 securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the
 consummation of the sale or disposition by the Company of all or substantially all of the
 Company's assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a
 change in the composition of the Board occurring within a two-year period, as a result of
 which fewer than a majority of the directors are Incumbent Directors. "Incumbent Directors"
 means directors who either (A) are Directors as of the Effective Date, or (B) are elected,
 or nominated for election, to the Board with the affirmative votes of at least a majority
 of the Incumbent Directors at the time of such election or nomination (but will not include
 an individual whose election or nomination is in connection with an actual or threatened
 proxy contest relating to the election of directors to the Company); or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the
 consummation of a merger or consolidation of the Company with any other corporation, other
 than a merger or consolidation which would result in the voting securities of the Company
 outstanding immediately prior thereto continuing to represent (either by remaining outstanding
 or by being converted into voting securities of the surviving entity or its parent) at least
 fifty percent (50%) of the total voting power represented by the voting securities of the
 Company or such surviving entity or its parent outstanding immediately after such merger
 or consolidation.

Notwithstanding the foregoing, a transaction shall not constitute a Change in Control if its sole purpose is to change the jurisdiction of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately before such transaction. In addition, if a Change in Control constitutes a payment event with respect to any Award which provides for a deferral of compensation and is subject to Code Section 409A, then notwithstanding anything to the contrary in the Plan or applicable Award Agreement, the transaction with respect to such Award must also constitute a "change in control event" as defined in Treasury Regulation 1.409A-3(i)(5) to the extent required by Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) " <u>Code</u> "
 means the Internal Revenue Code of 1986, as amended. Any reference to a section of the Code
 herein will be a reference to any successor or amended section of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) " <u>Company</u> "
 means Inhibitor Therapeutics, Inc., a Delaware corporation, or any successor thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) " <u>Consultant</u> "
 means a consultant or adviser who provides *bona fide* services to the Company, its
 Parent, or any Subsidiary as an independent contractor and who qualifies as a consultant
 or advisor under Instruction A.1.(a)(1) of Form S-8 under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) " <u>Director</u> "
 means a member of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) " <u>Disability</u> "
 means total and permanent disability as defined in Code Section 22(e)(3), provided that in
 the case of an Award other than an Incentive Stock Option, the Administrator in its discretion
 may determine whether a permanent and total disability exists in accordance with uniform
 and non-discriminatory standards adopted by the Administrator from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) " <u>Effective Date</u> " shall have the meaning set forth in Section 24.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) " <u>Employee</u> "
 means any person, including officers and Directors, employed by the Company, its Parent,
 or any Subsidiary. Neither service as a Director nor payment of a director's fee by
 the Company will be sufficient to constitute "employment" by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) " <u>Exchange Act</u> " means the Securities Exchange Act of 1934, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) " <u>Fair Market Value</u> " means, as of any date, the value of a Share, determined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if
 the Shares are readily tradable on an established securities market, its Fair Market Value
 will be the closing sales price for such shares (or the closing bid, if no sales were reported)
 as quoted on such market for the day of determination, as reported in <u>The Wall Street Journal</u> or such other source as the Administrator deems reliable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) if
 the Shares are regularly quoted by a recognized securities dealer but selling prices are
 not reported, its Fair Market Value will be the mean between the high bid and low asked prices
 for a Share for the day of determination, as reported in <u>The Wall Street Journal</u> or
 such other source as the Administrator deems reliable; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) if
 the Shares are not readily tradable on an established securities market, the Fair Market
 Value will be determined in good faith by the Administrator.

Notwithstanding the preceding, for federal, state, and local income tax reporting purposes and for such other purposes as the Administrator deems appropriate, Fair Market Value shall be determined by the Administrator in accordance with uniform and nondiscriminatory standards adopted by it from time to time. In addition, the determination of Fair Market Value in all cases shall be in accordance with the requirements set forth under Code Section 409A to the extent necessary for an Award to comply with, or be exempt from, Code Section 409A. The Administrator's determination shall be conclusive and binding on all persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) " <u>Incentive Stock Option</u> " means a Stock Option intended to qualify as an incentive stock option
 within the meaning of Code Section 422 and the regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) " <u>Non-Employee Director</u> " means a Director who is a "non-employee director" within
 the meaning of Exchange Act Rule 16b-3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) " <u>Nonqualified Stock Option</u> " means a Stock Option that by its terms, or in operation, does not
 qualify or is not intended to qualify as an Incentive Stock Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) " <u>Other Stock-Based Awards</u> " means any other awards not specifically described in the Plan
 that are valued in whole or in part by reference to, or are otherwise based on, Shares and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) " <u>Parent</u> "
 means a "parent corporation," whether now or hereafter existing, as defined in
 Code Section 424(e).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) " <u>Participant</u> "
 means the holder of an outstanding Award granted under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) " <u>Period of Restriction</u> " means the period during which the transfer of Restricted Stock
 is subject to restrictions and a substantial risk of forfeiture. Such restrictions may be
 based on the passage of time, the achievement of certain performance criteria, or the occurrence
 of other events as determined by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) " <u>Plan</u> "
 means this Inhibitor Therapeutics, Inc. 2025 Equity Incentive Plan, as amended and restated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) " <u>Restricted Stock</u> " means Shares, subject to a Period of Restriction or certain other specified
 restrictions (including, without limitation, a requirement that the Participant remain continuously
 employed or provide continuous services for a specified period of time), granted under Section
 9 or issued pursuant to the early exercise of a Stock Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) " <u>Restricted Stock Unit</u> " or " <u>RSU</u> " means an unfunded and unsecured promise
 to deliver Shares, cash, other securities, or other property, subject to certain restrictions
 (including, without limitation, a requirement that the Participant remain continuously employed
 or provide continuous services for a specified period of time), granted under Section 10.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) " <u>Retirement</u> "
 means the fulfillment of each of the following conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the
 Participant is in good standing with the Company and its affiliates as determined by the
 Administrator;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the
 Participant voluntarily terminates employment or other service with the Company and its affiliates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) at
 the time of such voluntary termination, the sum of: (A) the Participant's age (calculated
 to the nearest month, with any resulting fraction of a year being calculated as the number
 of months in the year divided by twelve (12))) and (B) the Participant's years of employment
 or other service with the Company and its affiliates (calculated to the nearest month, with
 any resulting fraction of a year being calculated as the number of months in the year divided
 by twelve (12)) equals at least sixty-two (62); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) at
 the time of such voluntary termination, the Participant is at least fifty-five (55) years
 of age and has been employed by or otherwise provided service to the Company and its affiliates
 for at least five (5) years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb) " <u>Service</u> "
 means service as a Service Provider. In the event of any dispute over whether and when Service
 has terminated, the Administrator shall have sole discretion to determine whether such termination
 has occurred and the effective date of such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc) " <u>Service Provider</u> " means an Employee, Director, or Consultant, including any prospective
 Employee, Director, or Consultant who has accepted an offer of employment or service and
 will be an Employee, Director, or Consultant after the commencement of their service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd) " <u>Stock Appreciation Right</u> " or " <u>SAR</u> " means an Award pursuant to Section
 8 that is designated as a SAR.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee) " <u>Shares</u> "
 means the Company's shares of common stock, par value of $0.0001 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ff) " <u>Stock Option</u> " means an option granted pursuant to the Plan to purchase Shares, whether
 designated as an Incentive Stock Option or a Nonqualified Stock Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg) " <u>Subsidiary</u> "
 means a "subsidiary corporation," whether now or hereafter existing, as defined
 in Code Section 424(f).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hh) " <u>Substitute Award</u> " has the meaning set forth in Section 3(d).

3. <u>Awards</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Award Types</u>. The Plan permits the grant of Stock Options, Stock Appreciation Rights, Restricted
 Stock, Restricted Stock Units, and Other Stock-Based Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Award Agreements</u>. Awards shall be evidenced by Award Agreements (which need not be identical,
 whether or not Participants are similarly situated) in such forms as the Administrator may
 from time to time approve; <u>provided</u>, <u>however</u>, that in the event of any conflict
 between the provisions of the Plan and any such Award Agreements, the provisions of the Plan
 shall prevail. The failure to specify any term of any Award in any particular Award Agreement
 shall not invalidate such term, provided such term was duly adopted by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Date of Grant</u>. The date of grant of an Award will be, for all purposes, the date on which
 the Administrator makes the determination granting such Award, or such later date as is determined
 by the Administrator, consistent with Applicable Laws. Notice of the determination will be
 provided to each Participant within a reasonable time after the date of such grant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Substitute Awards</u>. In connection with an entity's merger or consolidation with the Company,
 any Subsidiary, or the Company's or any Subsidiary's acquisition of an entity's
 property or stock, the Administrator may grant Awards in substitution for any options or
 other stock or stock-based awards granted before such merger or consolidation by such entity
 or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems
 appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not
 count against the Plan Share Limit (nor shall Shares subject to a Substitute Award be added
 to the Shares available for Awards under the Plan as provided below in Section 4(c), (d),
 or (e) below), except that Shares acquired by exercise of substitute Incentive Stock Options
 will count against the maximum number of Shares that may be issued pursuant to the exercise
 of Incentive Stock Options under Section 4(f). Additionally, in the event that a company
 acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines
 has shares available under a pre-existing plan (so long as not adopted in contemplation of
 such acquisition or combination), the shares available for grant pursuant to the terms of
 such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio
 or other adjustment or valuation ratio or formula used in such acquisition or combination
 to determine the consideration payable to the holders of common stock of the entities party
 to such acquisition or combination) may be used for Awards under the Plan, and shall not
 reduce the Plan Share Limit (and Shares available for Awards under the Plan as provided below
 in Section 4(c), (d), or (e) below); provided that Awards using such available shares shall
 not be made after the date awards or grants could have been made under the terms of the pre-existing
 plan, absent the acquisition or combination, and shall only be made to individuals who were
 not Service Providers prior to such acquisition or combination.

4. <u>Shares Available for Awards</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Basic Limitation</u>. Subject to the provisions of Section 14, the maximum aggregate number of
 Shares that may be issued under the Plan is Twenty Million (20 million) (the " <u>Plan Share Limit</u> "). The Shares subject to the Plan may be authorized, but unissued,
 or reacquired shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Annual Increase in Available Shares</u>. On the first day of each calendar year during the term
 of the Plan, commencing on January 1, 2027 and continuing until (and including) January 1,
 2035, the number of Shares available under the Plan Share Limit shall automatically increase
 by a number equal to the lesser of (i) One percent (1%) of the total number of Shares issued
 and outstanding on December 31 of the calendar year immediately preceding the date of such
 increase and (ii) a number of Shares determined by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Awards Not Settled in Shares Delivered to Participant</u>. Upon payment in Shares pursuant to the
 exercise or settlement of an Award, the number of Shares available for issuance under the
 Plan shall be reduced only by the number of Shares actually issued in such payment. If a
 Participant pays the exercise price (or purchase price, if applicable) of an Award through
 the tender of Shares, or if the Shares are tendered or withheld to satisfy any tax withholding
 obligations, the number of the Shares so tendered or withheld shall again be available for
 issuance pursuant to future Awards under the Plan, although such Shares shall not again become
 available for issuance as Incentive Stock Options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Cash-Settled Awards</u>. Shares shall not be deemed to have been issued pursuant to the Plan with respect
 to any portion of an Award that is settled in cash.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Lapsed Awards</u>. If any outstanding Award expires or is terminated or canceled without having
 been exercised or settled in full, or if the Shares acquired pursuant to an Award subject
 to forfeiture or repurchase are forfeited or repurchased by the Company, the Shares allocable
 to the terminated portion of such Award or such forfeited or repurchased Shares shall again
 be available for grant under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Code Section 422 Limitations</u>. No more than Ten Million (10,000,000) Shares (subject to adjustment
 pursuant to Section 14) may be issued under the Plan upon the exercise of Incentive Stock
 Options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Non—Employee Director Award Limit</u>. Notwithstanding any provision to the contrary in the Plan or in
 any policy of the Company regarding Non-Employee Director compensation, the sum of the grant
 date fair value (determined as of the grant date in accordance with Financial Accounting
 Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of
 all equity-based Awards and the maximum amount that may become payable pursuant to all cash-based
 Awards that may be granted to a Service Provider as compensation for services as a Non-Employee
 Director during any calendar year shall not exceed **$400,000** for such Service Provider's
 first year of service as a Non-Employee Director and **$300,000** for each year thereafter.
 A Non-Employee Director may receive additional equity-based and/or cash-based Awards for
 other additional services provided to the Company and its affiliates, provided such services
 are unrelated to service as a Non-Employee Director.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Share Reserve</u>. The Company, during the term of the Plan, shall at all times keep available
 such number of Shares authorized for issuance as will be sufficient to satisfy the requirements
 of the Plan.

5. Administration.
 The Plan will be administered by the Administrator.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Powers of the Administrator</u>. In addition to other express powers and authorizations conferred
 on the Administrator by this Plan, its charter, or the Company's bylaws, the Administrator
 will, subject to the provisions of the Plan, have the authority, in its discretion to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) determine
 Fair Market Value;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) select
 the Service Providers to whom Awards may be granted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) determine
 the type or types of Awards to be granted to Participants under the Plan and number of the
 Shares to be covered by each Award;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) approve
 forms of Award Agreements for use under the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) determine
 the terms and conditions, not inconsistent with the terms of the Plan, of any Award. Such
 terms and conditions include, but are not limited to, the exercise price, the time or times
 when Awards may be exercised (which may be based on performance criteria), any vesting criteria
 or Periods of Restriction, any vesting acceleration or waiver of forfeiture or repurchase
 restrictions, and any restriction or limitation regarding any Award or the Shares relating
 thereto, based in each case on such factors as the Administrator, in its sole discretion,
 will determine;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) construe
 and interpret the terms of the Plan, any Award Agreement, and Awards granted pursuant to
 the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) prescribe,
 amend, and rescind rules and regulations relating to the Plan, including rules and regulations
 relating to sub-plans established for the purpose of satisfying applicable foreign laws and/or
 qualifying for preferred tax treatment under applicable tax laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) modify
 or amend each Award (subject to Section 18(c)), including (A) the discretionary authority
 to extend the post-termination exercisability period of Awards and (B) accelerate the satisfaction
 of any vesting criteria or waiver of forfeiture or repurchase restrictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) allow
 Participants to satisfy withholding tax obligations by electing to have the Company withhold
 from the Shares or cash to be issued upon exercise or vesting of an Award that number of
 the Shares or cash having a Fair Market Value equal to the amount required to be withheld.
 The Fair Market Value of any Shares to be withheld will be determined on the date that the
 amount of tax to be withheld is to be determined. All elections by a Participant to have
 Shares or cash withheld for this purpose will be made in such form and under such conditions
 as the Administrator may deem necessary or advisable;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) authorize
 any person to execute on behalf of the Company any instrument required to effect the grant
 of an Award previously granted by the Administrator;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) allow
 a Participant to defer the receipt of the payment of cash or the delivery of the Shares that
 would otherwise be due to such Participant under an Award, subject to compliance (or exemption)
 from Code Section 409A;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) determine
 whether Awards will be settled in cash, Shares, other securities, other property, or in any
 combination thereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) determine
 whether Awards will be adjusted for dividend equivalents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) create
 Other Stock-Based Awards for issuance under the Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) impose
 such restrictions, conditions, or limitations as it determines appropriate as to the timing
 and manner of any resales by a Participant or other subsequent transfers by the Participant
 of any securities issued as a result of or under an Award, including without limitation,
 (A) restrictions under an insider trading policy, and (B) restrictions as to the use of a
 specified brokerage firm for such resales or other transfers; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) make
 all other determinations and take any other action deemed necessary or advisable for administering
 the Plan and due compliance with Applicable Laws, stock market or exchange rules or regulations
 or accounting or tax rules or regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Prohibition on Repricing</u>. Notwithstanding anything to the contrary in Section 5(a) and except for
 an adjustment pursuant to Section 14 or a repricing approved by stockholders, in no case
 may the Administrator (i) amend an outstanding Stock Option or SAR Award to reduce the exercise
 price of the Award, (ii) cancel, exchange, or surrender an outstanding Stock Option or SAR
 in exchange for cash or other awards for the purpose of repricing the Award, or (iii) cancel,
 exchange, or surrender an outstanding Stock Option or SAR in exchange for an option or SAR
 with an exercise price that is less than the exercise price of the original Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Section 16</u>. To the extent desirable to qualify transactions hereunder as exempt under Exchange
 Act Rule 16b-3, the transactions contemplated hereunder will be approved by the entire Board
 or a committee of two or more Non-Employee Directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Delegation of Authority</u>. Except to the extent prohibited by Applicable Laws, the Administrator may
 delegate to one or more officers of the Company some or all of its authority under the Plan,
 including the authority to grant all types of Awards, in accordance with Applicable Law (except
 that such delegation shall not apply to any Award for a Participant then covered by Section
 16 of the Exchange Act), and the Administrator may delegate to one or more committees of
 the Board (which may consist solely of one Director) some or all of its authority under this
 Plan, including the authority to grant all types of Awards, in accordance with Applicable
 Law. Such delegation may be revoked at any time. The acts of such delegates shall be treated
 as acts of the Administrator, and such delegates shall report regularly to the Administrator
 regarding the delegated duties and responsibilities and any Awards granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Effect of Administrator's Decision</u>. The Administrator's decisions, determinations,
 and interpretations will be final and binding on all persons, including Participants and
 any other holders of Awards.

6. <u>Eligibility</u>.
 The Administrator has the discretion to select any Service Provider to receive an Award,
 although Incentive Stock Options may be granted only to Employees. Designation of a Participant
 in any year shall not require the Administrator to designate such person to receive an Award
 in any other year or, once designated, to receive the same type or amount of Award as granted
 to the Participant in any other year. The Administrator shall consider such factors as it
 deems pertinent in selecting Participants and in determining the type and amount of their
 respective Awards.

7. <u>Stock Options</u>. The Administrator, at any time and from time to time, may grant Stock Options
 under the Plan to Service Providers. Each Stock Option shall be subject to such terms and
 conditions consistent with the Plan as the Administrator may impose from time to time, subject
 to the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Exercise Price</u>. The per share exercise price for Shares to be issued pursuant to exercise of a
 Stock Option will be determined by the Administrator, but shall be no less than 100% of the
 Fair Market Value per Share on the date of grant, subject to Section 7(e), or be less than
 the par value per Share. Notwithstanding the foregoing, in the case of a Stock Option that
 is a Substitute Award, the exercise price for Shares subject to such Stock Option may be
 less than the Fair Market Value per Share on the date of grant; provided that the exercise
 price of any Substitute Award shall be determined in accordance with the applicable requirements
 of Code Sections 424 and 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Exercise Period</u>. Stock Options granted under the Plan shall be exercisable at such time or times
 and subject to such terms and conditions as shall be determined by the Administrator; <u>provided</u>, <u>however</u>, that no Stock Option shall be exercisable later than ten (10) years after
 the date it is granted. Stock Options shall terminate at such earlier times and upon such
 conditions or circumstances as the Administrator shall in its discretion set forth in such
 Award Agreement at the date of grant; <u>provided</u>, <u>however</u>, the Administrator
 may, in its sole discretion, later waive any such condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Payment of Exercise Price</u>. To the extent permitted by Applicable Laws, the Participant may pay
 the Stock Option exercise price by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) cash;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) check;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) surrender
 of other Shares which meet the conditions established by the Administrator to avoid adverse
 accounting consequences to the Company (as determined by the Administrator);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) if
 approved by the Administrator, as determined in its sole discretion, by a broker-assisted
 cashless exercise in accordance with procedures approved by the Administrator, whereby payment
 of the exercise price may be satisfied, in whole or in part, with Shares subject to the Stock
 Option by delivery of an irrevocable direction to a securities broker (on a form prescribed
 by the Administrator) to sell Shares and to deliver all or part of the sale proceeds to the
 Company in payment of the aggregate exercise price;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) if
 approved by the Administrator for a Nonqualified Stock Option, as determined in its sole
 discretion, by delivery of a notice of "net exercise" to the Company, pursuant
 to which the Participant shall receive the number of Shares underlying the Stock Option so
 exercised reduced by the number of Shares equal to the aggregate exercise price of the Stock
 Option divided by the Fair Market Value on the date of exercise;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) such
 other consideration and method of payment for the issuance of Shares to the extent permitted
 by Applicable Laws; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) any
 combination of the foregoing methods of payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Exercise of Stock Option</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Procedure for Exercise</u>. Any Stock Option granted hereunder will be exercisable according to the
 terms of the Plan and at such times and under such conditions as determined by the Administrator
 and set forth in the Award Agreement. A Stock Option may not be exercised for a fraction
 of a Share. Exercising a Stock Option in any manner will decrease the number of Shares thereafter
 available for purchase under the Stock Option, by the number of Shares as to which the Stock
 Option is exercised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Exercise Requirements</u>. A Stock Option will be deemed exercised when the Company receives: (A)
 written or electronic notice of exercise (in accordance with the Award Agreement) from the
 person entitled to exercise the Stock Option, and (B) full payment of the exercise price
 (including provision for any applicable tax withholding).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Non-Exempt Employees</u>. If a Stock Option is granted to an Employee who is a non-exempt employee for
 purposes of the Fair Labor Standards Act of 1938, as amended, the Stock Option will not be
 first exercisable for any Shares until at least six (6) months following the date of grant
 of the Stock Option (although the Stock Option may vest prior to such date). Consistent with
 the provisions of the Worker Economic Opportunity Act, (A) if such non-exempt Employee dies
 or suffers a Disability, (B) upon a Change in Control in which such Stock Option is not assumed,
 continued, or substituted, or (C) upon the Participant's retirement (as such term may
 be defined in the Participant's Award Agreement, in another agreement between the Participant
 and the Company, or, if no such definition, in accordance with the then current employment
 policies and guidelines of the Company or employing Subsidiary), the vested portion of any
 Stock Option may be exercised earlier than six (6) months following the date of grant. The
 foregoing provision is intended to operate so that any income derived by a non-exempt employee
 in connection with the exercise or vesting of a Stock Option will be exempt from the Participant's
 regular rate of pay. To the extent permitted and/or required for compliance with the Worker
 Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection
 with the exercise, vesting, or issuance of any Shares under any other Award will be exempt
 from the employee's regular rate of pay, the provisions of this Section 7(d)(iii) will
 apply to all Awards and are hereby incorporated by reference into such Award Agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Termination of Relationship as a Service Provider</u>. If a Participant ceases to be a Service Provider,
 the Participant may exercise the Stock Option within such period of time as is specified
 in the Award Agreement to the extent that the Stock Option is vested on the date of termination
 (but in no event later than the expiration of the term of such Stock Option as set forth
 in the Award Agreement). In the absence of a specified time in the Award Agreement, the Stock
 Option will remain exercisable for (A) twelve (12) months following the Participant's
 termination on account of Disability or death; (B) the remainder of the Stock Option term
 in the case of an Employee or Director whose termination is on account of Retirement (it
 being understood that any Incentive Stock Option held by the Participant shall be treated
 as a Nonqualified Stock Option if exercise is not undertaken within ninety (90) days of the
 Retirement); or (C) four (4) months following the Participant's termination for all
 other terminations. Notwithstanding the foregoing, if a Participant commits an act of Cause,
 all vested and unvested Stock Options shall be forfeited as of such date. Unless otherwise
 provided by the Administrator, if on the date of termination the Participant is not vested
 as to a Stock Option, the Shares covered by the unvested portion of the Stock Option will
 be forfeited and will revert to the Plan and again will become available for grant under
 the Plan. If after termination, the Participant does not exercise a Stock Option as to all
 of the vested Shares within the time specified by the Administrator, the Stock Option will
 terminate, and remaining Shares covered by such Stock Option will be forfeited and will revert
 to the Plan and again will become available for grant under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Extension of Exercisability</u>. A Participant may not exercise a Stock Option at any time that the
 issuance of Shares upon such exercise would violate Applicable Laws. Except as otherwise
 provided in the Award Agreement, if a Participant ceases to be a Service Provider for any
 reason other than for Cause and, at any time during the last thirty (30) days of the applicable
 post-termination exercise period: (A) the exercise of the Participant's Stock Option
 would be prohibited solely because the issuance of Shares upon such exercise would violate
 Applicable Laws, or (B) the immediate sale of any Shares issued upon such exercise would
 violate the Company's trading policy, then the applicable post-termination exercise
 period will be extended to the last day of the calendar month that commences following the
 date the Award would otherwise expire, with an additional extension of the exercise period
 to the last day of the next calendar month to apply if any of the foregoing restrictions
 apply at any time during such extended exercise period, generally without limitation as to
 the maximum permitted number of extensions); <u>provided</u>, <u>however</u>, that in no
 event may such Award be exercised after the expiration of its maximum term.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <u>Beneficiary</u>.
 If a Participant dies while a Service Provider, the Stock Option may be exercised following
 the Participant's death by the Participant's designated beneficiary, provided
 such beneficiary has been designated and received by the Administrator prior to the Participant's
 death in a form acceptable to the Administrator. If no such beneficiary has been properly
 designated by the Participant, then such Stock Option may be exercised by the personal representative
 of the Participant's estate or by the persons to whom the Stock Option is transferred
 pursuant to the Participant's will or in accordance with the laws of descent and distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) <u>Stockholder Rights</u>. Until the Shares are issued (as evidenced by the appropriate entry on the books
 of the Company or of a duly authorized transfer agent or depositary of the Company), no right
 to vote or receive dividends or any other rights as a stockholder will exist with respect
 to the Shares, notwithstanding the exercise of the Stock Option. No adjustment will be made
 for a dividend or other right for which the record date is prior to the date the Shares are
 issued, except as provided in Section 14 or the applicable Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Incentive Stock Option Limitations</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each
 Stock Option will be designated in the Award Agreement as either an Incentive Stock Option
 or a Nonqualified Stock Option. However, notwithstanding such designation, to the extent
 that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock
 Options are exercisable for the first time by the Participant during any calendar year (under
 all plans of the Company, its Parent, or any Subsidiary) exceeds $100,000, such Stock Options
 will be treated as Nonqualified Stock Options. For purposes of this Section 7(e)(i), Incentive
 Stock Options will be taken into account in the order in which they were granted. The Fair
 Market Value of the Shares will be determined as of the time the Stock Option is granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) In
 the case of an Incentive Stock Option, the term will be ten (10) years from the date of grant
 or such shorter term as may be provided in the Award Agreement. Moreover, in the case of
 an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option
 is granted, owns shares representing more than ten percent (10%) of the total combined voting
 power of all classes of stock of the Company, its Parent, or any Subsidiary, the term of
 the Incentive Stock Option will be five (5) years from the date of grant or such shorter
 term as may be provided in the Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) No
 Stock Option shall be treated as an Incentive Stock Option unless this Plan has been approved
 by the shareholders of the Company in a manner intended to comply with the shareholder approval
 requirements of Code Section 422(b)(1), provided that any Stock Option intended to be an
 Incentive Stock Option shall not fail to be effective solely on account of a failure to obtain
 such approval, but rather such Stock Option shall be treated as a Nonqualified Stock Option
 unless and until such approval is obtained.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) In
 the case of an Incentive Stock Option, the terms and conditions of such grant shall be subject
 to and comply with such rules as may be prescribed by Code Section 422. If for any reason
 a Stock Option intended to be an Incentive Stock Option (or any portion thereof) shall not
 qualify as an Incentive Stock Option, then, to the extent of such nonqualification, such
 Stock Option or portion thereof shall be regarded as a Nonqualified Stock Option appropriately
 granted under this Plan.

8. <u>Stock Appreciation Rights</u>. The Administrator, at any time and from time to time, may grant
 SARs to Service Providers. Each SAR shall be subject to such terms and conditions, consistent
 with the Plan, as the Administrator may impose from time to time, subject to the following
 limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>SAR Award Agreement</u>. Each SAR Award will be evidenced by an Award Agreement that will specify
 the exercise price, the term of the SAR, the conditions of exercise, and such other terms
 and conditions as the Administrator, in its sole discretion, will determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Number of Shares</u>. The Administrator will have complete discretion to determine the number of
 Shares subject to any SAR Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Exercise Price and Other Terms</u>. The per share exercise price for the Shares that will determine
 the amount of the payment to be received upon exercise of a SAR will be determined by the
 Administrator and will be no less than one hundred percent (100%) of the Fair Market Value
 per Share on the date of grant. Notwithstanding the foregoing, in the case of a SAR that
 is a Substitute Award, the exercise price for Shares subject to such SAR may be less than
 the Fair Market Value per Share on the date of grant; provided that the exercise price of
 any Substitute Award shall be determined in accordance with the applicable requirements of
 Code Sections 424 and 409A. Otherwise, the Administrator, subject to the provisions of the
 Plan, will have complete discretion to determine the terms and conditions of SARs granted
 under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Expiration of Stock Appreciation Rights</u>. A SAR granted under the Plan will expire upon the date
 determined by the Administrator, in its sole discretion, and set forth in the Award Agreement.
 Notwithstanding the foregoing, the rules of Section 7(d) relating to the maximum term and
 exercise also will apply to SARs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Payment of Stock Appreciation Right Amount</u>. Upon exercise of a SAR, a Participant will be entitled
 to receive payment from the Company in an amount determined by multiplying:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The
 difference between the Fair Market Value of a Share on the date of exercise over the exercise
 price; times

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The
 number of Shares with respect to which the SAR is exercised.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Payment Form</u>. At the discretion of the Administrator, the payment upon SAR exercise may be in
 cash, in Shares, other securities, or other property of equivalent value, or in some combination
 thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Tandem Awards</u>. Any Stock Option granted under this Plan may include tandem SARs (<u>i.e.</u>,
 SARs granted in conjunction with an Award of Stock Options under this Plan). The Administrator
 also may award SARs to a Service Provider independent of any Stock Option.

9. <u>Restricted Stock</u>. The Administrator, at any time and from time to time, may grant Restricted Stock
 to Service Providers in such amounts as the Administrator, in its sole discretion, will determine,
 subject to the following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Restricted Stock Agreement</u>. Each Award of Restricted Stock will be evidenced by an Award Agreement
 that will specify the Period of Restriction and the applicable restrictions, the number of
 Shares granted, and such other terms and conditions as the Administrator, in its sole discretion,
 will determine. Restricted Stock may be awarded in consideration for (i) cash, check, bank
 draft or money order payable to the Company, (ii) past services to the Company, its Parent,
 or any Subsidiary, or (iii) any other form of legal consideration (including future services)
 that may be acceptable to the Administrator, in its sole discretion, and permissible under
 Applicable Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Restrictions</u>.
 Upon the grant of Restricted Stock, a book entry in a restricted account shall be established
 in the Participant's name at the Company's transfer agent, and, if the Administrator
 determines that the Restricted Stock shall be held by the Company or in escrow rather than
 held in such restricted account pending the release of the applicable restrictions, the Administrator
 may require the Participant to additionally execute and deliver to the Company (i) an escrow
 agreement satisfactory to the Administrator, if applicable, and (ii) the appropriate share
 power (endorsed in blank) with respect to the Restricted Stock covered by such agreement.
 If a Participant shall fail to execute an agreement evidencing an Award of Restricted Stock
 and, if applicable, an escrow agreement and blank share power within the amount of time specified
 by the Administrator, the Award shall be null and void *ab initio*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Voting Rights</u>. During the Period of Restriction, a Participant holding Restricted Stock may
 exercise the voting rights applicable to those restricted Shares, unless the Administrator
 determines otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Dividends and Other Distributions</u>. During the Period of Restriction, a Participant holding Restricted
 Stock will be entitled to receive all dividends and other distributions paid with respect
 to such Restricted Stock unless otherwise provided in the Award Agreement. If any such dividends
 or distributions are paid in Shares, such Shares will be subject to the same restrictions
 on transferability and forfeitability as the Restricted Stock with respect to which they
 were paid.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Transferability</u>.
 Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated
 or hypothecated until the end of the applicable Period of Restriction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Return of Restricted Stock to Company</u>. On the date set forth in the Award Agreement, the Restricted
 Stock for which restrictions have not lapsed will be forfeited and will revert to the Company
 and again will become available for grant under the Plan.

10. <u>Restricted Stock Units (RSUs)</u>. The Administrator, at any time and from time to time, may grant RSUs
 under the Plan to Service Providers. Each RSU shall be subject to such terms and conditions,
 consistent with the Plan, as the Administrator may impose from time to time, subject to the
 following limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>RSU Award Agreement</u>. Each Award of RSUs will be evidenced by an Award Agreement that will
 specify the terms, conditions, and restrictions related to the grant, including the number
 of RSUs and such other terms and conditions as the Administrator, in its sole discretion,
 will determine.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Vesting Criteria and Other Terms</u>. The Administrator will set vesting criteria in its discretion,
 which, depending on the extent to which the criteria are met, will determine the number of
 RSUs that will be paid out to the Participant. The Administrator may set vesting criteria
 based upon the achievement of Company-wide, business unit, or individual goals (including,
 but not limited to, continued employment or Service), or any other basis determined by the
 Administrator in its discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Earning Restricted Stock Units</u>. Upon meeting the applicable vesting criteria, the Participant
 will be entitled to receive a payout as determined by the Administrator. Notwithstanding
 the foregoing, at any time after the grant of RSUs, the Administrator, in its sole discretion,
 may reduce or waive any vesting criteria that must be met to receive a payout.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Form and Timing of Payment</u>. Payment of earned RSUs will be made as soon as practicable after
 the date(s) determined by the Administrator and set forth in the Award Agreement. The Administrator,
 in its sole discretion, may settle earned RSUs in cash, Shares, other securities, other property,
 or a combination of both.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Voting and Dividend Equivalent Rights</u>. The holders of RSUs shall have no voting rights as the
 Company's stockholders. Prior to settlement or forfeiture, RSUs awarded under the Plan
 may, at the Administrator's discretion, provide for a right to dividend equivalents.
 Such right entitles the holder to be credited with an amount equal to all dividends paid
 on one Share while the RSU is outstanding. Dividend equivalents may be converted into additional
 RSUs. Settlement of dividend equivalents may be made in the form of cash, Shares, other securities,
 other property, or in a combination of the foregoing. Prior to distribution, any dividend
 equivalents shall be subject to the same conditions and restrictions as the RSUs to which
 they attach.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Cancellation</u>.
 On the date set forth in the Award Agreement, all unearned RSUs will be forfeited to the
 Company.

11. <u>Other Stock-Based Awards</u>. Other Stock-Based Awards may be granted either alone, in addition
 to, or in tandem with, other Awards granted under the Plan and/or cash awards made outside
 of the Plan, and may include the award of fully vested and unrestricted Shares. The Administrator
 shall have authority to determine the Service Providers to whom and the time or times at
 which Other Stock-Based Awards shall be made, the amount of such Other Stock-Based Awards,
 and all other conditions of the Other Stock-Based Awards including any dividend and/or voting
 rights.

12. <u>Vesting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Vesting Conditions</u>. Each Award may or may not be subject to vesting, a Period of Restriction,
 and/or other conditions as the Administrator may determine. Vesting shall occur, in full
 or in installments, upon satisfaction of the conditions specified in the Award Agreement.
 Vesting conditions may include Service-based conditions, performance-based conditions, such
 other conditions as the Administrator may determine, or any combination thereof. An Award
 Agreement may provide for accelerated vesting upon certain specified events.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Performance Criteria</u>. The Administrator may establish performance-based conditions for an Award which
 may be based on the attainment of specific levels of performance of the Company (and/or one
 or more Subsidiaries, divisions, business segments or operational units, or any combination
 of the foregoing) and may include, without limitation, any of the following: (i) net earnings
 or net income (before or after taxes); (ii) basic or diluted earnings per share (before or
 after taxes); (iii) revenue or revenue growth (measured on a net or gross basis); (iv) gross
 profit or gross profit growth; (v) operating profit (before or after taxes); (vi) return
 measures (including, but not limited to, return on assets, capital, invested capital, equity,
 or sales); (vii) cash flow (including, but not limited to, operating cash flow, free cash
 flow, net cash provided by operations and cash flow return on capital); (viii) financing
 and other capital raising transactions (including, but not limited to, sales of the Company's
 equity or debt securities); (ix) earnings before or after taxes, interest, depreciation and/or
 amortization; (x) gross or operating margins; (xi) productivity ratios; (xii) share price
 (including, but not limited to, growth measures and total stockholder return); (xiii) expense
 targets; (xiv) margins; (xv) productivity and operating efficiencies; (xvi) customer satisfaction;
 (xvii) customer growth; (xviii) working capital targets; (xix) measures of economic value
 added; (xx) inventory control; (xxi) enterprise value; (xxii) sales; (xxiii) debt levels
 and net debt; (xxiv) combined ratio; (xxv) timely launch of new facilities; (xxvi) client
 retention; (xxvii) employee retention; (xxviii) timely completion of new product rollouts;
 (xxix) cost targets; (xxx) reductions and savings; (xxxi) productivity and efficiencies;
 (xxxii) strategic partnerships or transactions; and (xxxiii) personal targets, goals or completion
 of projects. Any one or more of the performance criteria may be used on an absolute or relative
 basis to measure the performance of the Company and/or one or more Subsidiaries as a whole
 or any business unit(s) of the Company and/or one or more Subsidiaries or any combination
 thereof, as the Administrator may deem appropriate, or any of the above performance criteria
 may be compared to the performance of a selected group of comparison or peer companies, or
 a published or special index that the Administrator, in its sole discretion, deems appropriate,
 or as compared to various stock market indices. The Administrator also has the authority
 to provide for accelerated vesting of any Award based on the achievement of performance criteria
 specified in this paragraph. Any performance criteria that are financial metrics, may be
 determined in accordance with United States Generally Accepted Accounting Principles (" <u>GAA</u> P")
 or may be adjusted when established to include or exclude any items otherwise includable
 or excludable under GAAP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Default Vesting</u>. Unless otherwise set forth in an individual Award Agreement, each Award shall
 vest over a three (3) year period, with one-third (1/3) of the Award vesting on the first
 annual anniversary of the date of grant and the remaining portion vesting quarterly thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Leaves of Absence</u>. Unless the Administrator provides otherwise, vesting of Awards granted hereunder
 will be suspended during any Employee's unpaid leave of absence and will resume on
 the date the Employee returns to work on a regular schedule as determined by the Administrator; <u>provided</u>, <u>however</u>, that no vesting credit will be awarded for the time vesting
 has been suspended during such leave of absence. A Service Provider will not cease to be
 an Employee in the case of (i) any leave of absence approved by the Company or the employing
 Subsidiary, although any leave of absence not provided for in the applicable employee manual
 of the Company or employing Subsidiary needs to be approved by the Administrator, or (ii)
 transfers between locations of the Company or between the Company, its Parent, or any Subsidiary.
 For purposes of Incentive Stock Options, no leave of absence may exceed ninety (90) days,
 unless reemployment upon expiration of such leave is guaranteed by statute or contract. If
 reemployment upon expiration of a leave of absence approved by the Company or employing Subsidiary
 is not so guaranteed, then three (3) months following the 91st day of such leave any Incentive
 Stock Option held by the Participant will cease to be treated as an Incentive Stock Option
 and will be treated for federal tax purposes as a Nonqualified Stock Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) In
 the event a Service Provider's regular level of time commitment in the performance
 of services for the Company, its Parent, or any Subsidiary is reduced (for example, and without
 limitation, if the Service Provider is an Employee of the Company and the Employee has a
 change in status from a full-time Employee to a part-time Employee) after the date of grant
 of any Award to the Service Provider, the Administrator has the right in its sole discretion
 to (i) make a corresponding reduction in the number of Shares subject to any portion of such
 Award that is scheduled to vest or become payable after the date of such change in time commitment,
 and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment
 schedule applicable to such Award. In the event of any such reduction, the Service Provider
 will have no right with respect to any portion of the Award that is so reduced or extended.

13. <u>Non-Transferability of Awards</u>. Unless determined otherwise by the Administrator, an Award may not be sold,
 pledged, assigned, hypothecated, transferred, or disposed of in any manner, except to the
 Participant's estate or legal representative, and may be exercised, during the lifetime
 of the Participant, only by the Participant, although the Administrator, in its discretion,
 may permit Award transfers for purposes of estate planning or charitable giving. If the Administrator
 makes an Award transferable, such Award will contain such additional terms and conditions
 as the Administrator deems appropriate.

14. <u>Adjustments; Dissolution or Liquidation; Change in Control</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Adjustments</u>.
 In the event that any dividend or other distribution (whether in the form of cash, Shares,
 other securities, or other property), recapitalization, share split, reverse share split,
 reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange
 of Shares or other securities of the Company, or other change in the corporate structure
 of the Company affecting the Shares occurs such that an adjustment is determined by the Administrator
 (in its sole discretion) to be appropriate in order to prevent dilution or enlargement of
 the benefits or potential benefits intended to be made available under the Plan, then the
 Administrator shall, in such manner as it may deem equitable, adjust the number and class
 of Shares which may be delivered under the Plan, the number, class and price of Shares subject
 to outstanding awards, and the numerical limits in Section 4. Notwithstanding the preceding,
 the number of Shares subject to any Award always shall be a whole number.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Dissolution or Liquidation</u>. In the event of the proposed dissolution or liquidation of the Company,
 the Administrator will notify each Participant as soon as practicable prior to the effective
 date of such proposed transaction. The Administrator in its discretion may provide for a
 Participant to have the right to exercise an Award, to the extent applicable, until ten (10)
 days prior to such transaction as to all of the Shares covered thereby, including Shares
 as to which the Award would not otherwise be exercisable. In addition, the Administrator
 may provide that any Company repurchase option or forfeiture rights applicable to any Award
 shall lapse 100%, and that any Award vesting shall accelerate 100%, provided the proposed
 dissolution or liquidation takes place at the time and in the manner contemplated. To the
 extent it has not been previously vested and, if applicable, exercised, an Award will terminate
 immediately prior to the consummation of such proposed action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Change in Control</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In
 the event of a Change in Control, each outstanding Award shall be assumed or an equivalent
 award substituted by the acquiring or successor corporation or a parent of the acquiring
 or successor corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Unless
 determined otherwise by the Administrator, in the event that the successor corporation refuses
 to assume or substitute for the Award, the Participant shall fully vest in and have the right
 to exercise the Award as to all of the Shares, including those as to which it would not otherwise
 be vested or exercisable, all applicable restrictions will lapse, and all performance objectives
 and other vesting criteria will be deemed achieved at targeted levels. If a Stock Option
 is not assumed or substituted in the event of a Change in Control, the Administrator shall
 notify the Participant in writing or electronically that the Stock Option shall be exercisable,
 to the extent vested, for a period of up to fifteen (15) days from the date of such notice,
 and the Stock Option shall terminate upon the expiration of such period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) For
 the purposes of this Section 14(c), the Award shall be considered assumed if, following the
 Change in Control, the Award confers the right to purchase or receive, for each Share subject
 to the Award immediately prior to the Change in Control, the consideration (whether shares,
 cash, or other securities or property) received in the Change in Control by holders of Shares
 for each Share held on the effective date of the transaction (and if holders were offered
 a choice of consideration, the type of consideration chosen by the holders of a majority
 of the outstanding Shares); <u>provided</u>, <u>however</u>, that if such consideration received
 in the Change in Control is not solely common shares of the acquiring or successor corporation
 or its parent, the Administrator may, with the consent of the acquiring or successor corporation,
 provide for the consideration to be received, for each Share subject to the Award, to be
 solely common shares of the acquiring or successor corporation or its parent equal in fair
 market value to the per share consideration received by holders of Shares in the Change in
 Control. Payments under this provision may be delayed to the same extent that payment of
 consideration to the holders of the Shares in connection with the Change in Control is delayed
 as a result of escrows, earn outs, holdbacks, or any other contingencies. Notwithstanding
 anything herein to the contrary, an Award that vests, is earned, or is paid out upon the
 satisfaction of one or more performance goals will not be considered assumed if the Company
 or the acquiring or successor corporation modifies any of such performance goals without
 the Participant's consent; <u>provided</u>, <u>however</u>, that a modification to
 such performance goals only to reflect the acquiring or successor corporation's post-Change
 in Control corporate structure will not be deemed to invalidate an otherwise valid Award
 assumption.

15. <u>Taxes</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>General</u>.
 It is a condition to each Award under the Plan that a Participant or such Participant's
 successor shall make such arrangements that may be necessary, in the opinion of the Administrator
 or the Company, for the satisfaction of any federal, state, local, or foreign withholding
 tax obligations that arise in connection with any Award granted under the Plan. The Company
 shall not be required to issue any Shares or make any cash payment under the Plan unless
 such obligations are satisfied.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Share Withholding</u>. To the extent that Applicable Laws subject a Participant to tax withholding
 obligations, the Administrator may permit such Participant to satisfy all or part of such
 obligations by having the Company, its Parent, or a Subsidiary withhold all or a portion
 of any Share that otherwise would be issued to such Participant or by surrendering all or
 a portion of any Share that the Participant previously acquired. Such Share shall be valued
 on the date withheld or surrendered. Any payment of taxes by assigning Shares to the Company,
 its Parent, or a Subsidiary may be subject to restrictions, including any restrictions required
 by the Securities and Exchange Commission, accounting, or other rules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Discretionary Nature of Plan</u>. The benefits and rights provided under the Plan are wholly discretionary
 and, although provided by the Company, do not constitute regular or periodic payments. Unless
 otherwise required by Applicable Laws, the benefits and rights provided under the Plan are
 not to be considered part of a Participant's salary or compensation or for purposes
 of calculating any severance, resignation, redundancy or other end of service payments, vacation,
 bonuses, long-term service awards, indemnification, pension or retirement benefits, or any
 other payments, benefits, or rights of any kind. By acceptance of an Award, a Participant
 waives any and all rights to compensation or damages as a result of the termination of Service
 for any reason whatsoever insofar as those rights result or may result from this Plan or
 any Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Code Section 409A</u>. Awards will be designed and operated in such a manner that they are either
 exempt from the application of, or comply with, the requirements of Code Section 409A and
 will be construed and interpreted in accordance with such intent, except as otherwise determined
 in the sole discretion of the Administrator. To the extent that an Award or payment, or the
 settlement or deferral thereof, is subject to Code Section 409A, the Award will be granted,
 paid, settled, or deferred in a manner that will meet the requirements of Code Section 409A,
 such that the grant, payment, settlement, or deferral will not be subject to the additional
 tax or interest applicable under Code Section 409A. If a Participant is a "specified
 employee" (within the meaning of Treasury Regulation 1.409A-1(i)) at any time during
 the twelve (12)-month period ending on the date of his termination of employment, and any
 Award hereunder subject to the requirements of Code Section 409A is to be satisfied on account
 of the Participant's termination of employment, satisfaction of such Award shall be
 suspended until the date that is six (6) months after the date of such termination of employment
 or, if earlier, the date of the Participant's death.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Deferral of Award Settlement</u>. The Administrator, in its discretion, may permit selected Participants
 to elect to defer distributions of Restricted Stock or RSUs in accordance with procedures
 established by the Administrator to assure that such deferrals comply with applicable requirements
 of the Code. Any deferred distribution, whether elected by the Participant or specified by
 the Award Agreement or the Administrator, shall comply with Code Section 409A, to the extent
 applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Limitation on Liability</u>. Neither the Company, nor its Parent, nor any Subsidiary, nor any person
 serving as Administrator shall have any liability to a Participant in the event an Award
 held by the Participant fails to achieve its intended characterization under applicable tax
 law.

16. <u>No Rights as a Service Provider</u>. Neither the Plan, nor an Award Agreement, nor any Award
 shall confer upon a Participant any right with respect to continuing a relationship as a
 Service Provider, nor shall they interfere in any way with the right of the Participant or
 the right of the Company, its Parent, or any Subsidiary to terminate such relationship at
 any time, with or without cause.

17. <u>Recoupment Policy</u>. All Awards granted under the Plan, all amounts paid under the Plan and all Shares
 issued under the Plan shall be subject to recoupment, clawback, or recovery by the Company
 in accordance with Applicable Laws and with Company policy (whenever adopted) regarding same,
 whether or not such policy is intended to satisfy the requirements of the Dodd-Frank Wall
 Street Reform and Consumer Protection Act, the Sarbanes-Oxley Act, or other Applicable Laws,
 as well as any implementing regulations and/or listing standards.

18. <u>Amendment and Termination of the Plan</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Amendment and Termination</u>. The Board may at any time amend, alter, suspend, or terminate the Plan.
 The Administrator may, to the extent consistent with the terms of any applicable Award Agreement,
 waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue,
 cancel, or terminate, any Award theretofore granted or the associated Award agreement, prospectively
 or retroactively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Stockholder Approval</u>. The Company may obtain stockholder approval of any Plan amendment to the extent
 necessary or, as determined by the Administrator in its sole discretion, desirable to comply
 with Applicable Laws, including any amendment that (i) increases the number of Shares available
 for issuance under the Plan or (ii) changes the persons or class of persons eligible to receive
 Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Effect of Amendment or Termination</u>. No amendment, alteration, suspension, or termination of
 the Plan or any Award or Award Agreement will materially impair the rights of any Participant
 with respect to outstanding Awards, unless mutually agreed otherwise between the Participant
 and the Administrator, which agreement must be in writing and signed by the Participant and
 the Company. Termination of the Plan will not affect the Administrator's ability to
 exercise the powers granted to it hereunder with respect to Awards granted under the Plan
 prior to the date of such termination.

19. <u>Conditions Upon Issuance of Shares</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Legal Compliance</u>. Shares will not be issued pursuant to an Award unless the exercise of such
 Award and the issuance and delivery of such Shares will comply with Applicable Laws and will
 be further subject to the approval of counsel for the Company with respect to such compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Investment Representations</u>. As a condition to the exercise or receipt of an Award, the Company may
 require the person exercising or receiving such Award to represent and warrant at the time
 of any such exercise or receipt that the Shares are being purchased only for investment and
 without any present intention to sell or distribute such Shares if, in the opinion of counsel
 for the Company, such a representation is required or desirable.

20. <u>Severability</u>.
 Notwithstanding any contrary provision of the Plan or an Award Agreement, if any one or more
 of the provisions (or any part thereof) of this Plan or an Award Agreement shall be held
 invalid, illegal, or unenforceable in any respect, such provision shall be modified so as
 to make it valid, legal, and enforceable, and the validity, legality, and enforceability
 of the remaining provisions (or any part thereof) of the Plan or Award Agreement, as applicable,
 shall not in any way be affected or impaired thereby.

21. <u>Inability to Obtain Authority</u>. The inability of the Company to obtain authority from any regulatory
 body having jurisdiction, which authority is deemed by the Company's counsel to be
 necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company
 of any liability in respect of the failure to issue or sell such Shares as to which such
 requisite authority will not have been obtained.

22. <u>Stockholder Approval</u>. The Plan will be subject to approval by the stockholders of the Company within
 twelve (12) months after the date the Plan is adopted. Such stockholder approval will be
 obtained in the manner and to the degree required under Applicable Laws. All Awards hereunder
 are contingent on approval of the Plan by stockholders. Notwithstanding any other provision
 of this Plan, if the Plan is not approved by the stockholders within twelve (12) months after
 the date the Plan is adopted, the Plan and any Awards hereunder shall be automatically terminated.

23. <u>Choice of Law</u>. The Plan will be governed by and construed in accordance with the internal laws
 of the State of Delaware, without reference to any choice of law principles.

24. <u>Effective Date</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Plan shall be effective as of October 21, 2025, the date on which the Plan was adopted by
 the Board subject to approval by the Company's shareholders as described in section
 22 above (the " <u>Effective Date</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Unless
 terminated earlier under Section 18, this Plan shall terminate on October 21, 2035, ten years
 after the Effective Date.